IR@PKUHSC  > 北京大学第一临床医学院  > 肿瘤化疗科
学科主题临床医学
Phase II trial of capecitabine combined with docetaxel in previously treated patients with non-small cell lung cancer: A randomized controlled study
Lin, Qiang1; Meng, Fan-Jie1; Liu, Yue&prime1; e(1)1; Wang, Na1; Ren, Xiao-Cang1; Chen, Xue-Ji1; Ge, Xiao-Hui2; Liu, Chao-Xing3; Hui, Jing1; Wang, Dong-Ying1; Cao, Bin1; Zhao, Yannan1
关键词Non-small Cell Lung Cancer Chemotherapy Second-line Therapy Capecitabine Docetaxel
刊名ONCOLOGY LETTERS
2012-04-01
DOI10.3892/ol.2012.575
3期:4页:761-766
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]2ND-LINE TREATMENT ; BREAST-CANCER ; COMBINATION ; THERAPY ; TUMORS
英文摘要

Docetaxel alone has been confirmed to be beneficial to patients with advanced previously treated non-small cell lung cancer (NSCLC). However, the duration and survival time is short. The study of two-agent combination regimens has important clinical significance. We conducted this randomized controlled phase II trial to comparatively evaluate the efficacy and side effects of capecitabine combined with docetaxel in previously treated patients with NSCLC. Patients with previously treated NSCLC who failed first-line chemotherapy were randomized into two groups; one received capecitabine combined with docetaxel (XT group) and the other received docetaxel alone (T group). Patients in the XT group received chemotherapy as follows: capecitabine 625 mg/m(2), p.o. bid, days 5-18; and docetaxel 30 mg/m(2), days 1 and 8, while patients in the T group received docetaxel 35 mg/m(2) on days I and 8. The primary endpoint was time to progression (TTP), and secondary endpoints were overall survival (OS), response rate (RR) and disease control rate (DCR). Forty-eight patients were recruited (23 in the Xi group and 25 in the T group). TIP, median survival time (MST) and I-year OS rate in the XT group and the T group were 7 months, 12 months, 47.6% and 3 months, 12 months, 39.6%, respectively. The TTP in the XT group was significantly longer compared to that in the T group (chi(2)=-4.763, p=0.029). The RR and DCR in the XT group and T group were 13.0% (3/23), 78.3% (18/23) and 12.0% (3/25), 76% (19/25), respectively. The difference was not significant (p>0.05). The major side effects observed in the two groups were neutropenia, fatigue and nausea, and toxicities were mild to modest. No severe cases of hand-foot syndrome were observed in the XT group. In conclusion, compared with docetaxel alone, capecitabine combined with docetaxel for patients with previously treated NSCLC achieved a significantly longer TIT and this regimen was well tolerated. The relatively high median TTP, 1-year OS rate and DCR encourage further evaluation of this regimen in a randomized phase III trial.

语种英语
WOS记录号WOS:000301307600005
引用统计
被引频次:3[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/51934
专题北京大学第一临床医学院_肿瘤化疗科
作者单位1.Hebei Med Univ, Affiliated N China Petr Bur, Gen Hosp, Dept Oncol, Renqiu City 062552, Hebei, Peoples R China
2.Hebei Univ, Affiliated Hosp, Dept Radiat Oncol, Baoding 071000, Hebei, Peoples R China
3.Beijing Univ, Hosp 1, Dept Radiat Oncol, Beijing 10034, Peoples R China
推荐引用方式
GB/T 7714
Lin, Qiang,Meng, Fan-Jie,Liu, Yue&prime,et al. Phase II trial of capecitabine combined with docetaxel in previously treated patients with non-small cell lung cancer: A randomized controlled study[J]. ONCOLOGY LETTERS,2012,3(4):761-766.
APA Lin, Qiang.,Meng, Fan-Jie.,Liu, Yue&prime.,e.,Wang, Na.,...&Zhao, Yannan.(2012).Phase II trial of capecitabine combined with docetaxel in previously treated patients with non-small cell lung cancer: A randomized controlled study.ONCOLOGY LETTERS,3(4),761-766.
MLA Lin, Qiang,et al."Phase II trial of capecitabine combined with docetaxel in previously treated patients with non-small cell lung cancer: A randomized controlled study".ONCOLOGY LETTERS 3.4(2012):761-766.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Lin, Qiang]的文章
[Meng, Fan-Jie]的文章
[Liu, Yue&prime]的文章
百度学术
百度学术中相似的文章
[Lin, Qiang]的文章
[Meng, Fan-Jie]的文章
[Liu, Yue&prime]的文章
必应学术
必应学术中相似的文章
[Lin, Qiang]的文章
[Meng, Fan-Jie]的文章
[Liu, Yue&prime]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。